This Article Full Text Full Text (PDF) Other Versions of this Article: IAI.00074-07v1 75/6/2818    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Liu, D.-F. Articles by Baker, S. M. Search for Related Content PubMed PubMed Citation Articles by Liu, D.-F. Articles by Baker, S. M.

 Previous Article  |  Next Article 

Infection and Immunity, June 2007, p. 2818-2825, Vol. 75, No. 6
0019-9567/07/$08.00+0     doi:10.1128/IAI.00074-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Moraxella catarrhalis Outer Membrane Protein CD Elicits Antibodies That Inhibit CD Binding to Human Mucin and Enhance Pulmonary Clearance of M. catarrhalis in a Mouse Model

Dai-Fang Liu,^* John C. McMichael, and Steven M. Baker

Wyeth Vaccines Research, Pearl River, New York 10965

Received 5 January 2007/ Returned for modification 25 February 2007/ Accepted 24 March 2007

The outer membrane protein CD of Moraxella catarrhalis is considered to be a potential vaccine antigen against Moraxella infection. We purified the native CD from isolate O35E, administered it to mice, and detected considerable titers of anti-CD antibodies. Anti-CD sera were cross-reactive towards six different M. catarrhalis isolates and promoted bacterial clearance of O35E in a pulmonary challenge model. To circumvent the difficulty of generating large quantities of CD from M. catarrhalis for vaccine use, the CD gene from O35E was cloned into Escherichia coli, and the recombinant CD, expressed without a signal sequence or fusion tags, represented 70% of the total E. coli proteins. The recombinant CD formed inclusion bodies that were solubilized with 6 M urea and then purified by ion-exchange chromatography, a procedure that produced soluble CD of high purity and yield. Mice immunized with the purified recombinant CD had significant titers of anti-CD antibodies that were cross-reactive towards 24 different M. catarrhalis isolates. Upon challenge, these mice showed enhanced bacterial clearance of both O35E and a heterologous M. catarrhalis isolate, TTA24. In an in vitro assay, antisera to either the native or the recombinant CD inhibited the binding activity of CD to human tracheobronchial mucin in a serum concentration-dependent manner, and the extent of inhibition appeared to correlate with the corresponding anti-CD antibody titer and whole-cell enzyme-linked immunosorbent assay titer. Our results demonstrate that the recombinant CD is a promising vaccine candidate for preventing Moraxella infection.

Published ahead of print on 2 April 2007.

Editor: A. Camilli

Present address: 186 Canterbury Rd., Rochester, NY 14607.

This article has been cited by other articles:

• Ruckdeschel, E. A., Kirkham, C., Lesse, A. J., Hu, Z., Murphy, T. F. (2008). Mining the Moraxella catarrhalis Genome: Identification of Potential Vaccine Antigens Expressed during Human Infection. Infect. Immun. 76: 1599-1607 [Abstract] [Full Text]  
• Luke, N. R., Jurcisek, J. A., Bakaletz, L. O., Campagnari, A. A. (2007). Contribution of Moraxella catarrhalis Type IV Pili to Nasopharyngeal Colonization and Biofilm Formation. Infect. Immun. 75: 5559-5564 [Abstract] [Full Text]